Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

NCT04949191 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04949191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04949191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
July 8, 2021
Completion date
April 11, 2024
Enrollment
10 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies